Summary & Overview
HCPCS G9109: Head and Neck Squamous Cell Disease-Status Assessment
HCPCS Level II code G9109 captures a disease-status assessment for early-stage head and neck cancers — specifically squamous cell carcinomas of the oral cavity, pharynx, and larynx — where initial staging is T1–T2, N0, M0 and there is no evidence of progression, recurrence, or metastasis. The code is designated for use within a Medicare-approved demonstration project and standardizes documentation of stable, early-stage disease prior to or independent of neo-adjuvant therapy. Nationally, standardized reporting of disease status supports comparative outcomes measurement, quality reporting in oncology initiatives, and demonstration-project evaluations.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise clinical context describing the intended use of the code, the typical service setting, and what the code represents in staging terms. The publication also summarizes payer coverage considerations, common modifiers associated with oncology service lines, and where applicable, links to related coding constructs or reporting efforts. This resource is intended to inform billing staff, oncology program managers, and policy analysts about the clinical and administrative role of HCPCS Level II code G9109 in national demonstration and reporting workflows.
Billing Code Overview
HCPCS Level II code G9109 describes an oncology disease-status assessment specific to head and neck cancer, limited to cancers of the oral cavity, pharynx, and larynx where squamous cell is the predominant histology. The code documents that the extent of disease was initially established as T1–T2, N0, M0 prior to any neo-adjuvant therapy and that there is no evidence of disease progression, recurrence, or metastases. This code is intended for use in a Medicare-approved demonstration project.
-
Service type: Disease-status assessment for early-stage head and neck squamous cell carcinoma
-
Typical site of service: Oncology clinic, outpatient cancer center, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old male with a newly diagnosed, biopsy-proven squamous cell carcinoma of the oral tongue staged clinically as T2 N0 M0 prior to any neoadjuvant therapy. The oncology multidisciplinary team (head and neck surgical oncology, radiation oncology, and medical oncology) documents baseline disease extent with tumor measurements, nodal evaluation (clinical exam and imaging such as contrast-enhanced CT or MRI of the neck), and absence of distant metastasis. The patient presents to an outpatient oncology clinic or hospital-based outpatient department for disease-status evaluation as part of a Medicare-approved demonstration project monitoring early-stage (T1–T2, N0, M0) head and neck squamous cell cancers limited to the oral cavity, pharynx, or larynx. Clinical workflow includes review of pathology, tumor board confirmation of staging, radiology review confirming no progression or metastasis, and documentation that disease remains limited (no recurrence) after primary diagnostic workup and any neoadjuvant therapy. The service is typically furnished by a head and neck surgeon or radiation oncologist in an outpatient surgical clinic, cancer center, or hospital outpatient setting and is used solely for reporting disease status under the demonstration project parameters.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | Use when no additional modifier is applicable and service is reported in routine fashion. |